RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 2×
“…p21/p27/p57 Cip/Kip family of CDK2:cyclin E inhibitors (Grimison et al., 2000; Jiang et al., 1998; Sherr and Roberts, 1999), seemingly to both sequester inhibitory activity away from CDK2:cyclin E complexes and, perhaps, to stabilize CDK4/6:cyclin D activity (Sherr and Roberts, 1999) (Figure 1).”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“…et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which phosphorylates RB in late G1, suggested that the p16 gene could be an important target for mutations in a wide range of…”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 1×
“Nonetheless, shortly after the validation of the RB gene as the locus that underlies the development of both familial and sporadic retinoblastoma (Friend et al., 1986; Lee et al., 1987), mutational inactivation of the RB gene was identified in approximately 90% of the common adult malignancy, small…”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 2×
“The almost simultaneous description of the p16 gene as the locus conferring susceptibility familial melanoma (Kamb et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which…”
BackgroundMost human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114 · cited 1×
“…lung, and thyroid, they are rarely detected in the endocrine tumors that arise from these same organs and may occur in 0% of medullary thyroid cancer and in 0% of neuroendocrine small cell lung cancer (Almoguera et al., 1988; Bockhorn et al., 2000; Capella et al., 1996; Mitsudomi et al., 1991).”
BackgroundMerlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986 · cited 1×
“…in identifying acquired somatic p16 mutations in tumors resulted from the unexpected observation that the p16 gene preferentially undergoes tumor-specific epigenetic gene silencing through promoter and exon 1 hypermethylation (Herman et al., 1995; Merlo et al., 1995; Otterson et al., 1995).”
BackgroundEffects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
BackgroundThe Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis
Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C.-C., Herrup, K., Lee, W.-H., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,265 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
Background
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Metadata
- Authors
- Kaye, F. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Kaye, Frederic J
- ORCID
- Kaye, Frederic J
- Venue
- Oncogene
- Published
- 2002-10-04
- Volume
- 21
- Issue
- 45
- Pages
- 6908-6914
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2081412587
- Cited by
- 153
- References
- 80
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 13 · 2013: 5 · 2012: 4
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- retinoblastoma protein, cyclin-dependent kinases, p16, tumor suppressor pathways, lung cancer, lung carcinogenesis, gene inactivation, epigenetic modifications, DNA tumor viruses, carcinogen exposure, targeted therapy
- MeSH terms
- Humans, Lung Neoplasms, Proto-Oncogene Proteins, Genes, Retinoblastoma, Gene Deletion, Carcinoma, Small Cell, Cyclin-Dependent Kinases, Genes, p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. https://app.cochat.ai/papers/10.1038/sj.onc.1205834
- The paper
- Kaye, F. J. (2002). RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene. https://doi.org/10.1038/sj.onc.1205834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.